EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1

EXELIXIS, INC.

Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026

$62.68+0.45 (+0.72%)

Close on Oct 19, 2026

Market cap: $16.28B
P/E (TTM): 19.7
Dividend yield: –

EXELIXIS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2026-01-02	FY 2024 2025-01-03	FY 2023 2023-12-29	FY 2022 2022-12-30	FY 2021 2021-12-31	FY 2020 2021-01-01	FY 2019 2020-01-03	FY 2018 2018-12-28	FY 2017 2017-12-29	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	2,320	2,169	1,830	1,611	1,435	988	968	854	452	191	37	25	31	47	290	185	152
Cost of Revenue	84	76	73	58	53	36	33	26	15	6.55	3.90	2.04	1.12	0	0	–	–
Gross Profit	2,236	2,092	1,758	1,553	1,382	951	935	827	437	185	33	23	30	47	290	–	–
Research & Development	825	910	1,044	892	694	548	337	182	112	96	96	189	179	129	157	211	235
Selling, General & Admin	519	492	543	460	402	293	228	206	159	116	57	51	51	32	33	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	32	33	33	34
Advertising Expenses	52	44	40	42	32	25	18	15	8.60	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	598	415	287	220	159	250	232	170	200	276	274
Total Costs & Expenses	1,448	1,564	1,659	1,410	1,148	877	598	415	–	–	–	–	–	–	–	–	–
Operating Income	872	605	171	201	287	110	369	439	166	-28	-121	-224	-201	-122	90	-91	-122
Interest Expense	–	–	–	–	–	–	0	0	8.68	33	41	41	39	25	16	9.34	13
Interest & Investment Income	69	77	87	33	7.67	20	28	13	4.88	2.58	0.79	–	–	–	–	–	–
Other Non-Operating Income	-0.20	-0.13	0.09	-0.20	-0.18	0.91	0.68	0.40	-7.33	-42	-40	-37	-38	-23	-13	-1.01	-19
Merger & Restructuring Charges	21	34	0	0	–	–	–	0	-0.03	0.91	1.04	7.60	1.23	9.17	10	33	–
Asset Impairment Charges	0	64	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	0	1.00	0.60	0	0	0	0	–
Pretax Income	–	–	–	–	–	131	398	452	159	-70	-162	-261	-245	-148	77	-92	-141
Income Tax Expense	159	160	50	52	63	19	77	-238	4.35	0	0.06	-0.18	-0.10	0.11	1.30	-0.07	-1.29
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	-245	-148	76	-92	-140
Net Income	783	521	208	182	231	112	321	690	154	-70	-162	-261	-238	-145	76	-92	-135
Net Income to Common	–	–	–	–	–	–	321	690	154	-70	-162	–	–	–	–	–	–
EPS (Basic)(per share)	2.88	1.80	0.65	0.57	0.73	0.36	1.06	2.32	0.52	-0.28	-0.77	-1.34	-1.29	-0.91	0.60	-0.85	-1.26
EPS (Diluted)(per share)	2.78	1.76	0.65	0.56	0.72	0.35	1.02	2.21	0.49	-0.28	-0.77	-1.34	-1.29	-0.91	0.58	-0.85	-1.26
Shares Outstanding (Basic, Weighted)(shares)	272	290	318	322	315	308	303	298	294	251	209	194	184	160	126	109	107
Shares Outstanding (Diluted, Weighted)(shares)	282	296	321	325	322	318	315	313	312	251	209	194	184	160	130	109	107
EBITDA	901	633	197	222	300	119	378	444	167	-27	-120	-222	-198	-117	96	-81	-109

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 3, 2026

Profitability, TTM

Gross margin: 96.5%
Operating margin: 39.9%
Net margin: 35.3%
Return on equity, FY2025: 35.5%

Financial strength

Current ratio: 3.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 77.8%

Valuation

P/E ratio: 19.7
Price to sales: 6.68
Price to book: 8.83
Dividend yield: –